Abstract 431P
Background
Glioma is one of the most common types of tumor of the central nervous system with high morbidity and mortality. Based on this fact that the prognosis of patients with high- grade glioma is poor, it is very important to develop new diagnostic and therapeutic strategies covering more efficient methods and drugs. Recent studies have demonstrated that Long non-coding RNAs (lncRNAs) may act as potential inducers or suppressors of numerous types of tumors including glioma. Besides, there are more expression of lncRNAs than coding mRNAs and miRNAs in specific tissues.In this study we evaluated two lncRNAs including MEG3 and MDC1-AS1 which seemed to be involved in the initiation and progression of high grade Gliomas.
Methods
The expression of lncRNAs were studied on 150 paraffin tissue block samples of Iranian participants, including 37 samples of low-grade gliomas(I&II), 58 samples of high grade glioma (III& IV) and 95 samples of non-tumoral tissues. After RNA extraction and complementary DNA synthesis(cDNA), probe-based (Taqman) Real-time PCR were used to evaluate lncRNAs expression level followed by statistical analizing.
Results
Our analysis, indicates that lncRNAs including MEG3 and MDC-AS1 are down-regulated (p =0.001) in high grade glioma tumors (grade III & IV) in comparison to low grade gliomas (grade I and II) and non-tumoral tissues.
Conclusions
The results show that there are critical expression differences i n MEG3 and MDC1-AS1 lncRNAs as tumor suppressor genes between high and low-grade gliomas. Comprising with other reports, it could be assumed that expression of MEG3 and MDC1-AS1 lncRNAs may serve as potential biomarkers and also therapeutic targets for detection and treatment of glioma tumors. Key words: Quantitative, lncRNAs, glioma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Arash Moradi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
285P - Comparison of induction chemotherapy plus concurrent chemoradiotherapy and concurrent chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma: A meta-analysis
Presenter: Xu Guoqiang
Session: e-Poster Display Session
286P - Improved diagnostic accuracy on MR imaging in post-surgical recurrent head and neck SCC lesions using decision tree classification system
Presenter: Ankush Jajodia
Session: e-Poster Display Session
287P - Establishment of nasopharyngeal carcinoma organoid culture system and preliminary exploration of drug sensitivity test in vitro
Presenter: Wang Wen
Session: e-Poster Display Session
288P - Application of volumetric modulated arc therapy (VMAT) in head and neck cancers: 5-year single institutional experience
Presenter: Hiep Doan
Session: e-Poster Display Session
289P - Radiotherapy in advanced nasopharyngeal carcinoma
Presenter: Chih Kiang Tan
Session: e-Poster Display Session
292P - Shared decision-making at the cancer institute adult outpatient clinics of a tertiary hospital in the Philippines: A cross sectional study
Presenter: Marvin Jonne Mendoza
Session: e-Poster Display Session
293P - Prolonged release (PR) oxycodone/naloxone (OXN) for cancer pain (CP) & its impact on bowel function, safety & quality of life (QoL): Systematic review
Presenter: Sam Hjelmeland Ahmedzai
Session: e-Poster Display Session
294P - Interventional pain treatment in patients with pain syndrome in advanced tumours of small pelvis
Presenter: Yakhyo Ziyaev
Session: e-Poster Display Session
295P - Assessment of the impact of palliative care on the quality of life in advanced non-small cell lung cancer patients
Presenter: Sabin Katpattil
Session: e-Poster Display Session
296P - Outcomes of repeat transhepatic percutaneous biliary drainage in patients presenting with recurrent malignant biliary stricture
Presenter: Deevia Hanji
Session: e-Poster Display Session